When Don Stranathan was diagnosed with stage IV non–small cell lung cancer (NSCLC) in 2009, genetic testing of NSCLC tumors was in its infancy. By 2015, when a new tumor was found in his left lung, Stranathan knew he wanted to learn as much as he could about his tumor’s genetics.
Stranathan’s doctors began by testing his tumor for mutations in the genes EGFR and ALK. But no alterations were found. Concerned that testing for one mutation at a time would use up his biopsied tumor tissue, the 64-year-old patient advocate from Santa Rosa, California, had a sample of his tumor sent to Foundation Medicine, whose FoundationOne test sequences 315 cancer-related genes and checks for rearrangements and changes in some other genes.
No comments:
Post a Comment